Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology
Icosavax creates virus-like particles using technology licensed from the University of Washington’s Institute for Protein Design. (Icosavax photo) New financing: At a moment when everyone is talking about vaccines, a Seattle-based biotech company taking an unusual approach to vaccine production raised $ 100 million in a Series B round. The startup creates computerized, virus-like particles … Read more